Institution
St George's, University of London
Education•London, United Kingdom•
About: St George's, University of London is a education organization based out in London, United Kingdom. It is known for research contribution in the topics: Population & Health care. The organization has 4953 authors who have published 11675 publications receiving 574153 citations. The organization is also known as: SGUL & St George's Hospital Medical School.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In post-MI patients with LVEF>30%, SAF identifies a high-risk group equivalent in size and mortality risk to patients withLVEF ≤ 30%, which doubled the sensitivity of mortality prediction and preserved 5-year mortality rate.
Abstract: Aims To investigate the combination of heart rate turbulence (HRT) and deceleration capacity (DC) as risk predictors in post-infarction patients with left ventricular ejection fraction (LVEF) > 30%.
Methods and results We enrolled 2343 consecutive survivors of acute myocardial infarction (MI) ( 30% (cumulative 5-year mortality rates of 37.9% and 7.8%, respectively). Among patients with LVEF > 30%, SAF identified another high-risk group of 117 patients with 37 deaths (cumulative 5-year mortality rates of 38.6% and 6.1%, respectively). Merging both high-risk groups (i.e. LVEF ≤ 30% and/or SAF) doubled the sensitivity of mortality prediction compared with LVEF ≤ 30% alone (21.1% vs. 42.1%, P < 0.001) while preserving 5-year mortality rate (38.2%).
Conclusion In post-MI patients with LVEF>30%, SAF identifies a high-risk group equivalent in size and mortality risk to patients with LVEF ≤ 30%.
181 citations
••
TL;DR: A diagnostic test for familial hypertrophic cardiomyopathy that relies on the detection of mutations in the beta myosin heavy-chain gene in circulating lymphocytes that is applicable to other diseases in which direct analysis is difficult because the mutated gene is expressed only in certain tissues is found.
Abstract: Background. The clinical diagnosis of familial hypertrophic cardiomyopathy is usually made on the basis of the physical examination, electrocardiogram, and echocardiogram. Making an accurate diagno...
181 citations
••
TL;DR: There is no convincing evidence that mupirocin treatment reduces the incidence of surgical site infection, and new antibiotics are needed to decolonize the nose because bacterial resistance to m upirocin is rising, and so it will become less effective.
Abstract: Staphylococcus aureus in the nose is a risk factor for endogenous staphylococcal infection. UK guidelines recommend the use of mupirocin for nasal decolonization in certain groups of patients colonized with methicillin-resistant S. aureus (MRSA). Mupirocin is effective at removing S. aureus from the nose over a few weeks, but relapses are common within several months. There are only a few prospective randomized clinical trials that have been completed with sufficient patients, but those that have been reported suggest that clearance of S. aureus from the nose is beneficial in some patient groups for the reduction in the incidence of nosocomial infections. There is no convincing evidence that mupirocin treatment reduces the incidence of surgical site infection. New antibiotics are needed to decolonize the nose because bacterial resistance to mupirocin is rising, and so it will become less effective. Furthermore, a more bactericidal antibiotic than mupirocin is needed, on the grounds that it might reduce the relapse rate, and so clear the patient of MRSA for a longer period of time than mupirocin.
181 citations
••
TL;DR: The efficacy and safety of inhaled MgSO₄ administered in acute asthma was determined and results were inconsistent overall and the largest study reporting this outcome found no between-group difference at 60 minutes.
Abstract: Acute asthma is a common emergency department problem usually treated with systemic corticosteroids, inhaled beta-agonists and a variety of other agents (including inhaled corticosteroids, inhaled anticholinergics, intravenous magnesium sulfate and oxygen). A Cochrane review showed that intravenous treatment with magnesium sulfate was helpful in improving peak expiratory flow measures (patients capacity to breathe more freely) in acute severe exacerbations of asthma. Therefore, we were interested in finding out if inhaled magnesium sulfate is helpful to people suffering an asthma attack and we undertook this review to explore this question.
Inhaled magnesium sulfate is recommended only after someone experiencing an asthma attack has been given bronchodilators, steroids and has failed to respond adequately to them. This review found that using inhaled magnesium sulfate combined with a beta-2-agonist (with or without ipratropium) for an acute asthma attack does not significantly improve pulmonary function (and therefore does not help people to breathe more freely) overall, but there may be improvement in adults with particularly severe asthma attacks, which merits further study The evidence, however, that the addition of nebulised magnesium sulfate is helpful with regard to clinically important outcomes, such as reducing hospital admissions, is not proven by the clinical trials included in this review.
181 citations
••
TL;DR: In this article, the authors conducted a systematic review of sleep apnoea drug therapy using the Cochrane Airways Group Specialised Register of trials and found that the overall quality of the available evidence was low.
Abstract: Background
The treatment of choice for moderate to severe obstructive sleep apnoea (OSA) is continuous positive airways pressure (CPAP) applied via a mask during sleep. However, this is not tolerated by all individuals and its role in mild OSA is not proven. Drug therapy has been proposed as an alternative to CPAP in some patients with mild to moderate sleep apnoea and could be of value in patients intolerant of CPAP. A number of mechanisms have been proposed by which drugs could reduce the severity of OSA. These include an increase in tone in the upper airway dilator muscles, an increase in ventilatory drive, a reduction in the proportion of rapid eye movement (REM) sleep, an increase in cholinergic tone during sleep, an increase in arousal threshold, a reduction in airway resistance and a reduction in surface tension in the upper airway.
Objectives
To determine the efficacy of drug therapies in the specific treatment of sleep apnoea.
Search methods
We searched the Cochrane Airways Group Specialised Register of trials. Searches were current as of July 2012.
Selection criteria
Randomised, placebo controlled trials involving adult patients with confirmed OSA. We excluded trials if continuous positive airways pressure, mandibular devices or oxygen therapy were used. We excluded studies investigating treatment of associated conditions such as excessive sleepiness, hypertension, gastro-oesophageal reflux disease and obesity.
Data collection and analysis
We used standard methodological procedures recommended by The Cochrane Collaboration.
Main results
Thirty trials of 25 drugs, involving 516 participants, contributed data to the review. Drugs had several different proposed modes of action and the results were grouped accordingly in the review. Each of the studies stated that the participants had OSA but diagnostic criteria were not always explicit and it was possible that some patients with central apnoeas may have been recruited.
Acetazolamide, eszopiclone, naltrexone, nasal lubricant (phosphocholinamine) and physiostigmine were administered for one to two nights only. Donepezil in patients with and without Alzheimer's disease, fluticasone in patients with allergic rhinitis, combinations of ondansetrone and fluoxetine and paroxetine were trials of one to three months duration, however most of the studies were small and had methodological limitations. The overall quality of the available evidence was low.
The primary outcomes for the systematic review were the apnoea hypopnoea index (AHI) and the level of sleepiness associated with OSA, estimated by the Epworth Sleepiness Scale (ESS). AHI was reported in 25 studies and of these 10 showed statistically significant reductions in AHI.
Fluticasone in patients with allergic rhinitis was well tolerated and reduced the severity of sleep apnoea compared with placebo (AHI 23.3 versus 30.3; P < 0.05) and improved subjective daytime alertness. Excessive sleepiness was reported to be altered in four studies, however the only clinically and statistically significant change in ESS of -2.9 (SD 2.9; P = 0.04) along with a small but statistically significant reduction in AHI of -9.4 (SD 17.2; P = 0.03) was seen in patients without Alzheimer's disease receiving donepezil for one month. In 23 patients with mild to moderate Alzheimer's disease donepezil led to a significant reduction in AHI (donepezil 20 (SD 15) to 9.9 (SD 11.5) versus placebo 23.2 (SD 26.4) to 22.9 (SD 28.8); P = 0.035) after three months of treatment but no reduction in sleepiness was reported. High dose combined treatment with ondansetron 24 mg and fluoxetine 10 mg showed a 40.5% decrease in AHI from the baseline at treatment day 28. Paroxetine was shown to reduce AHI compared to placebo (-6.10 events/hour; 95% CI -11.00 to -1.20) but failed to improve daytime symptoms.
Promising results from the preliminary mirtazapine study failed to be reproduced in the two more recent multicentre trials and, moreover, the use of mirtazapine was associated with significant weight gain and sleepiness. Few data were presented on the long-term tolerability of any of the compounds used.
Authors' conclusions
There is insufficient evidence to recommend the use of drug therapy in the treatment of OSA. Small studies have reported positive effects of certain agents on short-term outcomes. Certain agents have been shown to reduce the AHI in largely unselected populations with OSA by between 24% and 45%. For donepezil and fluticasone, studies of longer duration with a larger population and better matching of groups are required to establish whether the change in AHI and impact on daytime symptoms are reproducible. Individual patients had more complete responses to particular drugs. It is possible that better matching of drugs to patients according to the dominant mechanism of their OSA will lead to better results and this also needs further study.
181 citations
Authors
Showing all 5006 results
Name | H-index | Papers | Citations |
---|---|---|---|
JoAnn E. Manson | 270 | 1819 | 258509 |
Paul M. Ridker | 233 | 1242 | 245097 |
George Davey Smith | 224 | 2540 | 248373 |
Peer Bork | 206 | 697 | 245427 |
Grant W. Montgomery | 157 | 926 | 108118 |
Naveed Sattar | 155 | 1326 | 116368 |
Alan S. Verkman | 146 | 771 | 70434 |
David P. Strachan | 143 | 472 | 105256 |
Sekar Kathiresan | 141 | 479 | 98784 |
Nick C. Fox | 139 | 748 | 93036 |
Andrew Steptoe | 137 | 1003 | 73431 |
Daniel I. Chasman | 134 | 484 | 72180 |
Joel N. Hirschhorn | 133 | 431 | 101061 |
Dan M. Roden | 132 | 859 | 67578 |
Hugh Watkins | 128 | 524 | 91317 |